Effect of propranolol (inderal) on exercise tolerance in angina pectoris.

Hamer, John; Grandjean, Thierry; Melendez, L. J.; Sowton, G. E.

doi:10.1136/hrt.28.3.414

Cited by 29 publications

(9 citation statements)

References 14 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Propranolol is commonly used to treat hypertension, angina and post-traumatic stress disorders [27]. Several studies employing different techniques on mice demonstrated that propranolol is localized primarily in the brain, lung and kidney [28].…”

Section: Msi Drug Distribution and Quantificationmentioning

confidence: 99%

Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as normalization factor

Hamm

Bonnel

Legouffe

et al. 2012

Journal of Proteomics

179

214

View full text Add to dashboard Cite

Section: Msi Drug Distribution and Quantificationmentioning

confidence: 99%

Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as normalization factor

Hamm

Bonnel

Legouffe

et al. 2012

Journal of Proteomics

179

214

View full text Add to dashboard Cite

“…med. 1967, 1, 610-612 Propranolol (Inderal), a potent adrenergic /-receptor antagonist (Black et al, 1965), is effective in the treatment of angina pectoris (Gillam and Prichard, 1965;Grant et al, 1966;Hamer et al, 1966) and various cardiac arrhythmias (Besterman and Friedlander, 1965 ;Rowlands et al, 1965). On rare occasions propranolol may precipitate or aggravate cardiac failure or produce a severe bradycardia (Bath, 1966;Stephen, 1966), and in asthmatic patients may produce a marked reduction in ventilatory function (McNeill, 1964).…”

Section: Preliminary Communicationsmentioning

confidence: 99%

Stimulation of adrenergic beta-receptors by orciprenaline.

Shanks¹,

Brick²,

Hutchison³

et al. 1967

BMJ

View full text Add to dashboard Cite

“…The slowing effect of this drug on the heart rate at rest and during exercise is well known and does not require further comment. A significant reduction in cardiac output after propranolol is a constant finding in man, both in health and in heart disease (Hamer and Sowton, 1965;Sowton and Hamer, 1966;Paley, McDonald, and Peters, 1965;Robinson et al, 1965;Harris et al, 1966), and in animals (Black and Rolett, 1965;Nakano and Kusakari, 1965 (Table II). Before injection of the drug, prominent V waves reaching 30 to 35 mm.…”

Section: Resultsmentioning

confidence: 96%

Cardio-circulatory effects of beta-adrenergic blockade in organic heart disease. Comparison between propranolol and CIBA 39,089-Ba.

Grandjean¹,

Rivier²

1968

Heart

Self Cite

View full text Add to dashboard Cite

Beta-adrenergic blockers are increasingly used in the treatment of angina pectoris (Hamer et al., 1964Srivastava, Dewar, and Newell, 1964; Gillam andPrichard, 1965, 1966;Keelan, 1965;Rabkin et al., 1966;Wolfson et al., 1966), cardiac arrhythmias (Stock and Dale, 1963;Ginn, Irons, and Orgain, 1965;Harrison, Griffin, and Fiene, 1965;Bath, 1966;Harris, 1966;Rowlands, Howitt, and Markman, 1965;Schamroth, 1966;Szekely et al., 1966), and some other less common conditions (Harrison et al., 1964). The danger of inducing or aggravating heart failure by beta-blockade remains a matter of controversy (Stephen, 1966). Whereas this risk has been considered as relatively small and acceptable by Snow (1965Snow ( , 1966, undesirable side-effects and sometimes severe complications related to the depressant action of propranolol on myocardial contractility have been reported, in isolated instances with fatal outcome (Fleckenstein et al., 1964;Vogel, 1965;Scheu, 1966;Luthy and Hegglin, 1966). This risk undoubtedly represents an important drawback to this kind of therapy.In the present study, propranolol was given intravenously to patients with organic disease of the left heart, and its circulatory effects were assessed during the course of standard pre-operative catheterization of the heart. In a second stage of this study, these effects were compared with those of CIBA 39,089-Ba, a new specific beta-adrenergic blocking agent. Fig. 1 shows the chemical structures of isoprenaline, propranolol, and CIBA 39,089-Ba. Fig. 2 shows that the two drugs are apparently equipotent beta-blockers in terms of their negative chronotropic effect. This study Received March 30, 1967. suggests that propranolol depresses myocardial contractility, and this effect correlates well with the severity of the heart disease. CIBA 39,089-Ba has a negative chronotropic effect fairly similar to that of propranolol, but produces a significantly less marked depression of myocardial contractility. RESULTSThe results are shown in Tables III and IV and in Fig. 3-7. Both drugs slowed the heart rate to much the same extent. At rest, the heart rate was reduced from 77 to 64 beats/min. (-16%) after BLE I

show abstract

Effect of propranolol (inderal) on exercise tolerance in angina pectoris.

Cited by 29 publications

References 14 publications

Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as normalization factor

Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as normalization factor

Stimulation of adrenergic beta-receptors by orciprenaline.

Cardio-circulatory effects of beta-adrenergic blockade in organic heart disease. Comparison between propranolol and CIBA 39,089-Ba.

Contact Info

Product

Resources

About